Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 Anal Biochem
1 Ann Palliat Med
1 Biochem Pharmacol
1 Cancer
4 Cancers (Basel)
1 Cell Biol Int
1 Cell Death Dis
1 Comput Math Methods Med
2 Eur Urol
2 Eur Urol Open Sci
1 Front Immunol
1 Front Oncol
1 Genomics
1 Int J Biol Sci
3 Int J Mol Sci
1 Int Urol Nephrol
1 iScience
1 J Big Data
1 J Clin Med
1 J Comp Pathol
1 J Urol
1 JNCI Cancer Spectr
1 Sci Rep
3 Urol Oncol
1 World J Surg Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anal Biochem

  1. GRUBA N, Musielak M, Rejmak W, Lesner A, et al
    Detection of ADAM15 in urine from patients with bladder cancer.
    Anal Biochem. 2022 Jul 7:114805. doi: 10.1016/j.ab.2022.114805.
    PubMed         Abstract available

    Ann Palliat Med

  2. YHIM HY, Jeon SY, Lee CH, Lee NR, et al
    Bilateral pleural effusion associated with atezolizumab in a patient with Lynch syndrome-related urothelial carcinoma: a case report.
    Ann Palliat Med. 2022;11:2162-2169.
    PubMed         Abstract available


  3. GRANTZAU T, Toft BG, Melchior LC, Elversang J, et al
    PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study.
    APMIS. 2022;130:498-506.
    PubMed         Abstract available

    Biochem Pharmacol

  4. CHEN C, Na X, Wang L, Yu R, et al
    High-throughput screening identifies stevioside as a potent agent to induce apoptosis in bladder cancer cells.
    Biochem Pharmacol. 2022 Jul 9:115166. doi: 10.1016/j.bcp.2022.115166.
    PubMed         Abstract available


  5. MARTINI A, Yu M, Raggi D, Joshi H, et al
    Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring.
    Cancer. 2022;128:2892-2897.
    PubMed         Abstract available

    Cancers (Basel)

  6. JIANG S, Redelman-Sidi G
    BCG in Bladder Cancer Immunotherapy.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  7. AMANTINI C, Maggi F, Rossi de Vermandois JA, Gubbiotti M, et al
    The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  8. HU X, Li G, Wu S
    Advances in Diagnosis and Therapy for Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  9. DE CARLO C, Valeri M, Rudini N, Zucali PA, et al
    Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

    Cell Biol Int

  10. LI Z, Ren D, Chen C, Sun L, et al
    OSU-T315 and doxorubicin synergistically induce apoptosis via mitochondrial pathway in bladder cancer cells.
    Cell Biol Int. 2022 Jul 13. doi: 10.1002/cbin.11855.
    PubMed         Abstract available

    Cell Death Dis

  11. XIANG Y, Lv D, Song T, Niu C, et al
    Tumor suppressive role of microRNA-139-5p in bone marrow mesenchymal stem cells-derived extracellular vesicles in bladder cancer through regulation of the KIF3A/p21 axis.
    Cell Death Dis. 2022;13:599.
    PubMed         Abstract available

    Comput Math Methods Med

  12. WANG L, Wu D, Wu S, Liu Y, et al
    The Effect of Narrative Nursing Intervention on Shame in Elderly Patients with Bladder Cancer after Ileal Bladder Replacement: A Cohort Study.
    Comput Math Methods Med. 2022;2022:4299919.
    PubMed         Abstract available

    Eur Urol

  13. SZABADOS B, Kockx M, Assaf ZJ, van Dam PJ, et al
    Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Eur Urol. 2022;82:212-222.
    PubMed         Abstract available

  14. RAI BP, Luis Dominguez Escrig J, Vale L, Kuusk T, et al
    Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.
    Eur Urol. 2022;82:182-192.
    PubMed         Abstract available

    Eur Urol Open Sci

  15. KULKARNI GS, Lilge L, Nesbitt M, Dumoulin-White RJ, et al
    A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2022;41:105-111.
    PubMed         Abstract available

  16. D'ANDREA D, Shariat SF, Soria F, Mari A, et al
    The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy.
    Eur Urol Open Sci. 2022;41:74-80.
    PubMed         Abstract available

    Front Immunol

  17. YI X, Zheng X, Xu H, Li J, et al
    IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Front Immunol. 2022;13:898493.
    PubMed         Abstract available

    Front Oncol

  18. WANG G, Gao Y, Chen Y, Wang K, et al
    Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development.
    Front Oncol. 2022;12:921711.
    PubMed         Abstract available


  19. PAN W, Han J, Wei N, Wu H, et al
    LINC00702-mediated DUSP1 transcription in the prevention of bladder cancer progression: Implications in cancer cell proliferation and tumor inflammatory microenvironment.
    Genomics. 2022 Jul 6:110428. doi: 10.1016/j.ygeno.2022.110428.
    PubMed         Abstract available

    Int J Biol Sci

  20. ZHOU Q, Chen S, Lu M, Luo Y, et al
    Erratum: EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/beta-catenin signaling pathway in human bladder cancer: Erratum.
    Int J Biol Sci. 2022;18:3798-3799.
    PubMed         Abstract available

    Int J Mol Sci

  21. WOLLNY T, Wnorowska U, Piktel E, Suprewicz L, et al
    Sphingosine-1-Phosphate-Triggered Expression of Cathelicidin LL-37 Promotes the Growth of Human Bladder Cancer Cells.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  22. PILISZEK R, Brozyna AA, Rudnicki WR
    Computational Analysis Identifies Novel Biomarkers for High-Risk Bladder Cancer Patients.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  23. BECKER L, Fischer F, Fleck JL, Harland N, et al
    Data-Driven Identification of Biomarkers for In Situ Monitoring of Drug Treatment in Bladder Cancer Organoids.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

    Int Urol Nephrol

  24. SAINI S, Pathak RA, Hemal AK
    Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care?
    Int Urol Nephrol. 2022;54:1777-1785.
    PubMed         Abstract available


  25. BONDARUK J, Jaksik R, Wang Z, Cogdell D, et al
    Erratum: The origin of bladder cancer from mucosal field effects.
    iScience. 2022;25:104715.
    PubMed         Abstract available

    J Big Data

  26. GUI CP, Li JY, Fu LM, Luo CG, et al
    Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer.
    J Big Data. 2022;9:88.
    PubMed         Abstract available

    J Clin Med

  27. PENA KB, Riu F, Hernandez A, Guilarte C, et al
    Usefulness of the Urine Methylation Test (Bladder EpiCheck((R))) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells-An Institutional Study.
    J Clin Med. 2022;11.
    PubMed         Abstract available

    J Comp Pathol

  28. HU SP, Zhang Z, Xiao F, Huang JN, et al
    Paraganglioma of the Urinary Bladder in a Dog.
    J Comp Pathol. 2022;195:1-6.
    PubMed         Abstract available

    J Urol

  29. MCELREE IM, Packiam VT, Steinberg RL, Mott SL, et al
    Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment OF NON-MUSCLE Invasive Bladder Cancer.
    J Urol. 2022 Jul 5:101097JU0000000000002848. doi: 10.1097/JU.0000000000002848.
    PubMed         Abstract available

    JNCI Cancer Spectr

  30. VADER DT, Parikh RB, Li H, Imai K, et al
    Impact of label restriction on checkpoint-inhibitor use in bladder cancer and changes in mortality.
    JNCI Cancer Spectr. 2022 Jul 9. pii: 6637519. doi: 10.1093.
    PubMed         Abstract available

    Sci Rep

  31. ZHAO X, Zhang L, Bai L, Zhao Y, et al
    Epidemiological analysis of second primary malignant neoplasms in cancer survivors aged 85 years and older: a SEER data analysis (1975-2016).
    Sci Rep. 2022;12:11688.
    PubMed         Abstract available

    Urol Oncol

  32. OMORPHOS NP, Ghose A, Hayes JDB, Kandala A, et al
    The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer.
    Urol Oncol. 2022 Jul 5. pii: S1078-1439(22)00187.
    PubMed         Abstract available

  33. CHU C, Pietzak E
    Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue "Seminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma".
    Urol Oncol. 2022 Jul 7. pii: S1078-1439(22)00185.
    PubMed         Abstract available

  34. AYDIN AM, Cheriyan SK, Reich R, Hajiran A, et al
    Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
    Urol Oncol. 2022 Jul 7. pii: S1078-1439(22)00192.
    PubMed         Abstract available

    World J Surg Oncol

  35. AZHATI B, Wu G, Zhan H, Liang W, et al
    Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
    World J Surg Oncol. 2022;20:231.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.